Kymera, with new data, takes early step toward a Dupixent-like pill
Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called STAT6 that’s implicated in many autoimmune conditions.
Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called STAT6 that’s implicated in many autoimmune conditions.
